Pacira生物科学 PCRX 深 沪
已收盘 01-30 16:00:00 美东时间
20.54
+0.450
+2.24%
华盛通- 最 高20.55
- 今 开20.08
- 成交量 49.67万股
- 最 低 19.94
- 昨 收 20.09
- 总市值 9.51亿
- 52周最高 27.64
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 18.80
- 委 比 24.27%
- 总股本 4630.47万
- 历史最高 121.95
- 量 比 0.71
- 振 幅 3.04%
- 历史最低 6.51
- 每 手 1
- 风险率 1.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
Pacira BioSciences, Inc. announced the appointment of Samit Hirawat, M.D., to its Board of Directors, expanding the Board to 10 members. Hirawat, a veteran in clinical development with over 25 years of experience, previously served as Chief Medical Officer and Head of Global Drug Development at Bristol Myers Squibb. He brings expertise in advancing innovative therapies, aligning with Pacira’s mission to deliver non-opioid pain solutions. Pacira’s...
01-28 13:00
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
Pacira BioSciences has granted LG Chem exclusive rights to distribute EXPAREL in select Asian-Pacific markets, expanding access to non-opioid pain management solutions. The partnership aims to address the high demand for long-acting post-surgical pain control and aligns with Pacira's 5x30 strategy. LG Chem will handle regulatory approvals in South Korea and Thailand, while Pacira will manufacture the product. The agreement includes an upfront pay...
01-13 13:00
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 19.2% to $1...
01-09 20:05
What Analysts Are Saying About Pacira BioSciences Stock
5 analysts have expressed a variety of opinions on Pacira BioSciences (NASDAQ:P...
01-09 20:01
Needham Maintains Buy on Pacira BioSciences, Maintains $30 Price Target
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $30 price target.
01-09 17:51
Pacira drops after adjusting 2025 revenue below consensus
Pacira BioSciences (PCRX) is down ~10% in after-hours trading Thursday after revising downwards its expectation for 2025 total revenues. The company reported preliminary full-year revenues of $726.4M....
01-09 06:49
Pacira reports preliminary FY25 revenue of $726.4M
Pacira BioSciences (PCRX) on Thursday reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, compared with $701.0 million for the year ended December 31,...
01-09 05:23
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
Pacira BioSciences reported preliminary 2025 revenue of $726.4 million, up 3.6% from 2024, driven by 7% growth in EXPAREL volume. Fourth-quarter EXPAREL sales rose 7% to $155.8 million, offsetting shifts in vial mix and discounting. Full-year EXPAREL sales reached $575.1 million, a 6% volume increase. ZILRETTA sales were stable, while iovera° sales rose slightly. The company repurchased 2.0 million shares in Q4 at a cost of $50.0 million, with $1...
01-08 21:01
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
Pacira BioSciences, Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 AM PST. The company will present live audio accessible via its website, with a webcast replay available for two weeks. Pacira, focused on innovative, non-opioid pain therapies, offers three commercial-stage treatments: EXPAREL®, ZILRETTA®, and iovera®º, and is advancing a pipeline for musculoskeletal pain, includ...
01-07 13:00
